IceCure Medical Yönetim

Yönetim kriter kontrolleri 4/4

IceCure Medical CEO'su Eyal Shamir, Sep2016 tarihinde atandı, in görev süresi 8.17 yıldır. in toplam yıllık tazminatı $ 553.00K olup, şirket hissesi ve opsiyonları dahil olmak üzere 75.3% maaş ve 24.7% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1.05% ine doğrudan sahiptir ve bu hisseler $ 404.64K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.9 yıl ve 6 yıldır.

Anahtar bilgiler

Eyal Shamir

İcra Kurulu Başkanı

US$553.0k

Toplam tazminat

CEO maaş yüzdesi	75.3%
CEO görev süresi	8.2yrs
CEO sahipliği	1.1%
Yönetim ortalama görev süresi	5.9yrs
Yönetim Kurulu ortalama görev süresi	6yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Eyal Shamir'un ücretlendirmesi IceCure Medical'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$14m
Jun 30 2024	n/a	n/a	-US$14m
Mar 31 2024	n/a	n/a	-US$14m
Dec 31 2023	US$553k	US$416k	-US$15m
Sep 30 2023	n/a	n/a	-US$16m
Jun 30 2023	n/a	n/a	-US$16m
Mar 31 2023	n/a	n/a	-US$16m
Dec 31 2022	US$658k	US$467k	-US$17m
Sep 30 2022	n/a	n/a	-US$16m
Jun 30 2022	n/a	n/a	-US$15m
Mar 31 2022	n/a	n/a	-US$13m
Dec 31 2021	US$489k	US$426k	-US$10m
Sep 30 2021	n/a	n/a	-US$8m
Jun 30 2021	n/a	n/a	-US$6m
Mar 31 2021	n/a	n/a	-US$4m
Dec 31 2020	US$420k	US$370k	-US$4m
Sep 30 2020	n/a	n/a	-US$4m
Jun 30 2020	n/a	n/a	-US$4m
Mar 31 2020	n/a	n/a	-US$4m
Dec 31 2019	n/a	n/a	-US$5m
Sep 30 2019	n/a	n/a	-US$5m
Jun 30 2019	n/a	n/a	-US$4m
Mar 31 2019	n/a	n/a	-US$4m
Dec 31 2018	US$350k	US$251k	-US$4m
Sep 30 2018	n/a	n/a	-US$3m
Jun 30 2018	n/a	n/a	-US$3m
Mar 31 2018	n/a	n/a	-US$3m
Dec 31 2017	US$312k	US$259k	-US$3m

Tazminat ve Piyasa: Eyal 'ın toplam tazminatı ($USD 553.00K ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 647.72K ).

Tazminat ve Kazançlar: Eyal 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Eyal Shamir (63 yo)

8.2yrs

Görev süresi

US$552,996

Tazminat

Mr. Eyal Shamir serves as Chief Executive Officer and Director at IceCure Medical Ltd. since September 2016 and December 2017 respectively. Mr. Shamir served as Chief Executive Officer of Tadbik Pack Ltd.,...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Eyal Shamir	CEO & Director	8.2yrs	US$553.00k	1.05% $ 404.6k
Ronen Tsimerman	CFO & COO	7.5yrs	US$405.26k	0.62% $ 239.0k
Tlalit Tel-Tzure	Vice President of Business Development & Global Marketing	5.9yrs	US$320.70k	0.32% $ 121.6k
Merav Dotan	Vice President of Human Resources	3yrs	US$282.17k	0.12% $ 45.2k
Galit Malik	Vice President of Operations & Service	1.9yrs	Veri yok	0.11% $ 43.8k

5.9yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim: ICCM 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.9 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Eyal Shamir	CEO & Director	6.9yrs	US$553.00k	1.05% $ 404.6k
Sharon Levita	Independent External Director	5.2yrs	US$205.58k	Veri yok
Oded Tamir	Independent External Director	11.2yrs	Veri yok	0.020% $ 7.8k
Ron Mayron	Chairman of the Board	6.9yrs	US$62.23k	0.45% $ 173.0k
Chun Hung Chan	Independent Director	1.9yrs	Veri yok	Veri yok
Yang Huang	Director	4.6yrs	Veri yok	0.15% $ 57.0k

6.0yrs

Ortalama Görev Süresi

61yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ICCM 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6 yıldır).

IceCure Medical Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

IceCure Medical Ltd, Annual General Meeting, May 20, 2024

Insufficient new directors

IceCure Appoints Vincent Chun Hung Chan to Serve as an Independent Director on its Board of Directors

IceCure Medical Ltd, Annual General Meeting, Mar 03, 2022

Recent updates

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

IceCure Medical Ltd to Report Q3, 2024 Results on Nov 26, 2024

IceCure Medical Ltd has filed a Follow-on Equity Offering.

IceCure Medical Ltd. Announces Study Publishes in British Journal of Radiology Demonstrates IceCure's ProSense is Safe Procedure with 97.7% Technical Success Rate in Treating Tumors of Lung, Bone, and Soft Tissues

IceCure Medical Ltd. Announces FDA Advisory Panel Meeting Date for Marketing Authorization of ProSense in Early-Stage Low Risk Breast Cancer Scheduled for November 7, 2024

U.S. Patent and Trademark Office Grants Notice of Allowance for Additional Patent on IceCure Medical Ltd.'s Novel Cryogenic Pump Technology

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Forecast to breakeven in 2026

IceCure Medical Ltd Announces the Publication of an Independent Study of Patients Who Chose Cryoablation for the Treatment of Early Breast Cancer in Non-Surgical Patients

IceCure Medical Ltd to Report Q2, 2024 Results on Aug 20, 2024

IceCure Medical Ltd. Announces Positive Data from the Largest Multi-Institutional Study of Its Kind: "Cryoablation of Primary Breast Cancer in Patients Ineligible for Clinical Trials

Is IceCure Medical (NASDAQ:ICCM) In A Good Position To Invest In Growth?

New minor risk - Share price stability

IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification

IceCure Medical Ltd. Announces the Publication of an Independent Study Evaluating its Cryoablation System ProSense

U.S. Food and Drug Administration Grants Regulatory Clearance to IceCure for Next-Gen XSense Cryoablation System with CryoProbes

New minor risk - Shareholder dilution

FDA to Convene Advisory Panel for Review of IceCure Medical Ltd.'s De Novo Marketing Clearance Request for ProSense®, Decision Expected Early 2025

First quarter 2024 earnings: EPS in line with expectations, revenues disappoint

IceCure Medical Ltd to Report Q1, 2024 Results on May 28, 2024

IceCure Medical Ltd, Annual General Meeting, May 20, 2024

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Icecure Submits FDA Regulatory Filing for New Xsense™ Cryoablation System with Cryoprobes

IceCure Medical Ltd to Report Fiscal Year 2023 Results on Apr 03, 2024

Price target increased by 14% to US$3.33

IceCure Medical Ltd. Reports Positive Topline Results from ICE3 Cryoablation Breast Cancer Study

IceCure Medical Ltd. Announces Results from an Independent Study

Icecure Medical Ltd. Announces New Data from A Preliminary, Independent Breast Cancer Study

IceCure Medical Ltd has filed a Follow-on Equity Offering in the amount of $9.7 million.

IceCure Medical Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

Forecast to breakeven in 2026

IceCure Medical Ltd. Announces the Publication of a Study Called "Cryoablation Allows the Ultimate De-Escalation of Surgical Therapy for Select Breast Cancer Patients

IceCure Medical Ltd. Announces Release of a Study in a Series of Independent Studies of ProSense

We're Keeping An Eye On IceCure Medical's (NASDAQ:ICCM) Cash Burn Rate

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

IceCure Medical Files Appeal with U.S. FDA Requesting a Review of its De Novo Classification for ProSense in Early-Stage Breast Cancer

IceCure Medical Ltd to Report Q3, 2023 Results on Nov 15, 2023

Icecure Medical Ltd. Announces Provides Update on Substantial Evidence-Based Data Currently Being Generated by 19 Ongoing Studies Using IceCure Medical's Prosense Cryoablation System

New major risk - Revenue and earnings growth

IceCure Medical Ltd. Receives FDA Response to De Novo Classification Request for Breast Cancer

Price target decreased by 15% to US$3.41

Icecure Medical's Prosense Cryoablation System Receives Regulatory Approval in Brazil

Icecure Medical's Prosense Cryoablation System Receives Regulatory Approval in Brazil

Second quarter 2023 earnings: EPS misses analyst expectations

IceCure Medical Ltd to Report Q2, 2023 Results on Aug 14, 2023

Is IceCure Medical (NASDAQ:ICCM) In A Good Position To Deliver On Growth Plans?

Health Canada Approves Icecure Medical's Minimally Invasive Prosense Cryoablation System

New major risk - Financial position

New major risk - Revenue and earnings growth

IceCure Medical Ltd to Report Q1, 2023 Results on May 22, 2023

Insufficient new directors

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Price target decreased by 14% to US$3.96

IceCure Medical Ltd Receives Notice of Allowance from the U.S. Patent and Trademark Office for Its Patent Application Titled Cryogen Pump

IceCure Medical Ltd Receives Notice of Patent Allowance in Japan for A Novel Cryogenic Pump for Its Next-Generation Cryoablation Systems

IceCure Medical Ltd Announces Interim Results from the ICESECRET Study for the Treatment of Patients with Small Renal Masses

IceCure Appoints Vincent Chun Hung Chan to Serve as an Independent Director on its Board of Directors

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

IceCure Medical Ltd to Report Nine Months, 2022 Results on Dec 05, 2022

Price target decreased to US$4.58

IceCure's ProSense® Achieves Significant Milestone in Medicare Coverage of Breast Cancer Procedures

Price target decreased to US$4.58

IceCure Medical Ltd. Files De Novo Classification Request with the FDA for Marketing Authorization of ProSense with Breakthrough Indication: Early-Stage Low-Risk Breast Cancer Patients at High Risk to Surgery

IceCure gains 19% on seeking FDA nod for cancer treatment

IceCure Medical Ltd Submits Regulatory Filing in Vietnam for Approval of Prosense®

Second quarter 2022 earnings released

IceCure Medical Ltd to Report Q2, 2022 Results on Aug 15, 2022

IceCure Medical Ltd Announces Regulatory Filing Submission for Approval of ProSense® in Canada for Indications Including Ablation of Benign and Malignant Breast Tumors

IceCure files application for approval of ProSense in Canada for tumors

IceCure Medical Ltd to Report Q1, 2022 Results on May 18, 2022

Price target decreased to US$7.58